A Phase 2B, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (FASCINATE-2)
Latest Information Update: 18 Oct 2024
At a glance
- Drugs Denifanstat (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms FASCINATE-2
- Sponsors Sagimet Biosciences
- 16 Oct 2024 According to a Sagimet Biosciences media release, data from this study will be presented at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting 2024, taking place November 15-19, 2024 in San Diego, California.
- 11 Oct 2024 According to a Sagimet Biosciences media release, results from the Phase 2b FASCINATE-2 clinical trial of denifanstat versus placebo in biopsy-confirmed metabolic-dysfunction associated steatohepatitis (MASH) patients with stage 2 or stage 3 fibrosis (F2/F3) were published in The Lancet Gastroenterology & Hepatology.
- 11 Oct 2024 Results presented in the Sagimet Biosciences Media Release.